Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer. Academic Article uri icon

Overview

abstract

  • Fourteen evaluable advanced breast cancer patients, extensively pretreated by chemotherapy, received a combination of cisplatin (DDP) and etoposide (VP 16). DDP was given at 60 or 100 mg/m2 on day 1, and VP 16 at 120 mg/m2 on days 1, 2 and 3; cycles were repeated every 4 weeks. Major responses were never obtained; a minor response in 1 patient, no change in 7 patients, and progression in 6 patients were observed. Main side effects were nausea and vomiting (62% severe), and leukopenia (31% leukocytes less than 2,000/mm3). Two patients refused further treatment due to intense nausea and vomiting. DDP-VP 16 combination chemotherapy is ineffective and poorly tolerated in heavily pretreated breast cancer patients.

publication date

  • April 30, 1988

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Cisplatin
  • Etoposide

Identity

Scopus Document Identifier

  • 0023927643

Digital Object Identifier (DOI)

  • 10.1177/030089168807400212

PubMed ID

  • 3368973

Additional Document Info

volume

  • 74

issue

  • 2